

Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



December 13, 2023

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Subject: General update – Inclusion of specialty product ILUMETRI, (Tildrakizumab Injection) in category B of China’s National Reimbursement Drug List

This is to inform you that our specialty product ILUMETRI, (Tildrakizumab Injection) is now included in category B of China’s National Reimbursement Drug List, which shall be officially implemented from January 1, 2024. ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

In June 2019, Sun Pharma had out-licensed Tildrakizumab to a subsidiary of China Medical System Holdings Limited (CMS), for the Greater China market. ILUMETRI was approved for marketing in China in May 2023. The inclusion of ILUMETRI in category B of the National Reimbursement Drug List will further improve the accessibility and affordability of the innovative drug to benefit more patients.

This is for your information and dissemination.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983